RBC Capital weighs in on Sarepta Therapeutics (SRPT) related to two new FAERS Elevidys deaths
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $14.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
